# Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery

> **NCT04420689** · PHASE1,PHASE2 · COMPLETED · sponsor: **Alume Biosciences, Inc.** · enrollment: 27 (actual)

## Conditions studied

- Parotid Neoplasm
- Thyroid Neoplasms
- Head and Neck Neoplasms
- Surgery
- Nerve Injury
- Imaging

## Interventions

- **DRUG:** Bevonescein

## Key facts

- **NCT ID:** NCT04420689
- **Lead sponsor:** Alume Biosciences, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-18
- **Primary completion:** 2021-06-25
- **Final completion:** 2022-02-15
- **Target enrollment:** 27 (ACTUAL)
- **Last updated:** 2025-05-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04420689

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04420689, "Bevonescein to Highlight Nerves in Patients Undergoing Head & Neck Surgery". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04420689. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*